• Breathtaking science

    Developing innovative therapeutics to transform

    the standard of care for respiratory diseases

  • Search for better science

    We aim to build a strong clinical R&D pipeline to

    target debilitating respiratory diseases

  • Our science

    Targeting respiratory diseases with significant unmet medical needs.

    There are millions of patients suffering globally from chronic, debilitating respiratory conditions that are not well treated by existing medicines. There is a real and pressing need for new treatments. We are focused on developing these treatments. Our efficient R&D outsourcing model gives us access to leading experts and organisations around the globe and our agility and focus on our core competencies provide the highest standards of pre-clinical and clinical development. 

    See our product pipeline

    Our strategy

    To progress projects with high commercial potential, whilst delivering both near-and long-term value to our shareholders.

    We have a clear view of the medical need and commercial potential of our novel products in global, multi-billion dollar markets. Making the right decisions now, with partners and investors, will help us identify the quickest and most effective route to market allowing us to potentially transform the lives of patients suffering from these debilating diseases, with the returns enabling us to continue this mission into the future. 

    Find out more about us

Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis. The Company is listed on the NASDAQ Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative theraputics.

Latest press releases

7 September 2017

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)
Ac…

21 August 2017

PDMR Dealing
LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage bi…

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva)

Webcast

September 7, 2017 at 08:00 AM EDT

Current share price

141.00p

0.50 (0.36%)

LON: VRP
 

15.00USD

0.06 (0.40%)

NASDAQ: VRNA
 

Contact us

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

E: info@veronapharma.com
T: +44 (0)203 283 4200

 

 

Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

Investor relations contact
ICR, Inc.
685 Third Avenue. 2nd Floor
New York, NY 10017

E: ICR_Verona@icrinc.com
T: +1 646 277 1282

 

Nominated adviser and broker
Stifel Nicolaus Europe Limited
150 Cheapside
London EC2V 6ET
United Kingdom

T: +44 (0)207 710 7600

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us